Arthritis, Rheumatoid, Crohn Disease
Conditions
Keywords
Crohn's Disease, Rheumatoid Arthritis
Brief summary
Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R.I.N.) will participate. This registry will be a multicentre, prospective, observational program that will gather and analyze data on subjects being treated with infliximab.
Interventions
None listed
Sponsors
Janssen Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Subject is a good candidate to receive infliximab as per the Product Monograph * Subject is prescribed infliximab by an appropriate physician * Subject receives infusion in a community infusion centre. * Subject has signed the approved consent form.
Exclusion criteria
* Not specified in the protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Type and frequency of infusion reactions | Up to 7 years |
| Pre-infusion treatments and efficacy | Up to 7 years |
| Infusion reaction management approaches | Up to 7 years |
| The number of subjects with adverse events | Up to 7 years |
Countries
Canada
Outcome results
None listed